Maxim initiated coverage of Autonomix (AMIX) with a Buy rating and $5 price target The company’s platform technology could transform the field of electrophysiology by detecting neural signals that indicate pain or disease and destroying those nerves at the source, the analyst tells investors in a research note. The firm says that while the initial focus is on pancreatic cancer pain, the technology has the potential to address multiple indications involving the peripheral nervous system, chronic pain management, hypertension, cardiovascular disease, and other tumor-related pain. It believes Autonomix has sufficient capital to operate into Q3 of fiscal 2026.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX: